HomeAI · summaries
Storia in 4 fonti
Biogen, Eisai announce new data on efficacy, safety of LEQEMBI SC-AI
Eisai (ESAIY) and Biogen (BIIB) announced that new data presented at the Alzheimer’s Association International Conference, AAIC, 2026 in London ...
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Subcutaneous, intravenous outcomes with lecanemab comparable in Alzheimer’s disease
Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according to a group of abstracts presented at the Alzheimer’s…
- ·
markets.businessinsider.com
Biogen, Eisai announce new data on efficacy, safety of LEQEMBI SC-AI
Eisai (ESAIY) and Biogen (BIIB) announced that new data presented at the Alzheimer’s Association International Conference, AAIC, 2026 in London ...
- ·
morningstar.com
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease…
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association…
- ·
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
- ·
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- ·
economictimes.indiatimes.com
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows patients to self-administer injections, improving…
- ·
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world…
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026